Reference Values of Intraepidermal Nerve Fiber Density in Children and Small Fiber Neuropathy in Neurodevelopmental Disorders
NCT ID: NCT05645874
Last Updated: 2025-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
203 participants
OBSERVATIONAL
2022-02-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Aims: In this study, we are establishing the reference values for the physiological IENFD in children from 0-18 years. Moreover, we are investigating if children with NDDs have a reduced IENFD and if SFN is a clinically relevant cause of pain and autonomic dysfunction.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Normative Data of Intra-epidermal Nerve Fiber Density
NCT01498211
Neuroma Injections to Treat Restless Legs Syndrome - RCT
NCT00656110
Spinal Cord Stimulation in Small Fibre Neuropathy
NCT02905396
Autofluorescent Flavoprotein Imaging of Intraepidermal Nerve Fibers: a Pilot Study
NCT02537951
Probing the Role of Sodium Channels in Painful Neuropathies
NCT02243475
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The IENFD is determined by staining and quantification of PGP9.5-positive intraepidermal nerve fibers on 40 µm thick skin sections.
The skin biopsies will be collected from the site of orthopedic surgical procedure. For example, if the child is undergoing corrective osteotomy of genu valgum, the skin biopsy is drawn from the most distal part of surgical incision sides (distal leg); if the child is undergoing orthopedic surgery in the context of epiphyseolysis capitis femoris, the skin biopsy is drawn from the thigh (proximal leg):
In adults, the IENFD is higher in specimens derived from the proximal leg than in skin from the distal leg. Because in small fiber neuropathy the small nerve fiber degeneration often starts distally, the recommended sampling site for the quantification of IENFD in adults is the distal leg. That is why the calculation of the 5th percentile as the cutoff for reduced IENFD in children will be based on skin biopsies collected from the distal leg.
Due to the limited number of surgeries on the distal leg and distal biopsies in certain age groups of healthy participants (e.g. 4-8), cases with skin biopsies taken from the proximal leg will also be included. The IENFD from cases drawn from the proximal leg and cases from the distal leg will be compared. The samples drawn from the distal or proximal leg will be labelled accordingly. If the IENFD is comparable between the distal and proximal cases, a pooled analysis including proximal and distal cases will be performed.
In the second part of the study, skin biopsies from the distal leg will be collected from children with neurodevelopmental disorders of acquired, genetic and initially unexplained etiology in the setting of local anesthesia, whenever possible during an elective intervention with sedation/general anesthesia. IENFD below the predicted age- and sex-specific 5th percentile will be classified "reduced", otherwise as "normal".
A literature review will be performed to identify those neurodevelopmental disorders that have been associated with peripheral neuropathy in the past.
In cases with a yet unexplained etiology of neurodevelopmental disorder (no perinatal asphyxia, postnatal asphyxia, no cardiopulmonary resuscitation, no extreme prematurity, no encephalitis others, no stroke, or cerebral tumor), genetic testing (exome or genome sequencing and microarray analysis) will be performed.
Clinical symptoms of SFN (distal sensory signs and autonomic dysfunction) In adults the diagnosis of SNF is also based on the presence of distal sensory signs. Therefore, all participants or their legal guardians will be requested to answer questionnaires \[(SFN-symptom inventory questionnaire (SFN-SIQ) and the SFN-Screening list (SFNSL)\] that specifically assess distal sensory and autonomic symptoms related to SFN.
Additional exploratory subgroup analysis 1): In adults the diagnosis of SNF is also based on abnormal thermal perception assessed by quantitative sensory testing (QST). In collaboration with the University Children´s Hospital of the Ruhr University Bochum, QST will be performed in those children that are old enough and who have the cognitive ability to undergo QST. Small nerve fiber function including thermal perception will be assessed.
Additional exploratory subgroup analysis 2): Small fiber neuropathy can be associated with large fiber neuropathy. Therefore, the proportion of abnormal findings of electrophysiological studies in medical record of children with a reduced versus normal IENFD will be assessed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control (no underlying neurological disorder)
Neurologically healthy individuals undergoing elective surgical intervention on the leg
Skin biopsy
Control skin biopsies from children without a chronic underlying disease are drawn from surgical crop margins during elective orthopedic surgery of the lower leg (n\<80). Skin punch biopsies from children with acquired (n\<80) or genetic NDD (n\<80) or unknown etiology (N\<80) are drawn in the setting of elective interventions during sedation or after local anesthesia. IENFD is quantified by immunohistochemistry and compared between the control and NDD group.
Neurodevelopmental disorder_Genetic cause known
Individuals with neurodevelopmental symptoms (developmental delay, muscular hypotonia, seizures, ataxia, etc) with age of onset before the age of 18 years. Genetic etiology, if a genetic diagnosis had been established before inclusion to the study
Skin biopsy
Control skin biopsies from children without a chronic underlying disease are drawn from surgical crop margins during elective orthopedic surgery of the lower leg (n\<80). Skin punch biopsies from children with acquired (n\<80) or genetic NDD (n\<80) or unknown etiology (N\<80) are drawn in the setting of elective interventions during sedation or after local anesthesia. IENFD is quantified by immunohistochemistry and compared between the control and NDD group.
Neurodevelopmental disorder_Acquird (cause known)
Individuals with neurodevelopmental symptoms (developmental delay, muscular hypotonia, seizures, ataxia, etc) with age of onset before the age of 18 years.
Acquired etiology, if a plausible cause of NDD was known (including but not limited to perinatal asphyxia, postnatal asphyxia or cardiopulmonary resuscitation, premature birth with periventricular leukomalacia, premature birth with severe intracranial bleeding, brain damage due to encephalitis, stroke, cerebral tumor; no red flags of genetic disease, such as syndromic features),
Skin biopsy
Control skin biopsies from children without a chronic underlying disease are drawn from surgical crop margins during elective orthopedic surgery of the lower leg (n\<80). Skin punch biopsies from children with acquired (n\<80) or genetic NDD (n\<80) or unknown etiology (N\<80) are drawn in the setting of elective interventions during sedation or after local anesthesia. IENFD is quantified by immunohistochemistry and compared between the control and NDD group.
Neurodevelopmental disorder_Unexplained etiology
Individuals with neurodevelopmental symptoms (developmental delay, muscular hypotonia, seizures, ataxia, etc) with age of onset before the age of 18 years.
Unexplained etiology, if there is no genetic diagnosis established so far and if there is no history of perinatal risk factors for brain injury or if there are other red flags for genetic cause (e.g., normal magnetic resonance findings or delayed myelination; findings suggestive of syndromic disease).
Skin biopsy
Control skin biopsies from children without a chronic underlying disease are drawn from surgical crop margins during elective orthopedic surgery of the lower leg (n\<80). Skin punch biopsies from children with acquired (n\<80) or genetic NDD (n\<80) or unknown etiology (N\<80) are drawn in the setting of elective interventions during sedation or after local anesthesia. IENFD is quantified by immunohistochemistry and compared between the control and NDD group.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Skin biopsy
Control skin biopsies from children without a chronic underlying disease are drawn from surgical crop margins during elective orthopedic surgery of the lower leg (n\<80). Skin punch biopsies from children with acquired (n\<80) or genetic NDD (n\<80) or unknown etiology (N\<80) are drawn in the setting of elective interventions during sedation or after local anesthesia. IENFD is quantified by immunohistochemistry and compared between the control and NDD group.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Interest to participate in the study, informed consent
* Unremarkable neurological development
* Neurodevelopmental problems (developmental delay, muscular hypotonia, seizures, ataxia,...) with age of onset before the age of 18 years
* Interest to participate in the study, informed consent
Exclusion Criteria
* Skin inflammation, scar, skin disease, other known chronic diseases that can cause small fiber pathology
Neurodevelopmental patients
* Known polyneuropathy
* Skin inflammation, scar, skin disease, other known chronic diseases that can cause small fiber pathology
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Heinrich-Heine University, Duesseldorf
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Felix Distelmaier
Role: PRINCIPAL_INVESTIGATOR
Department of General Pediatrics, Heinrich-Heine-University, Düsseldorf, Germany.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Düsseldord, Department of General Pediatrics, Neonatology and Pediatric Cardiology
Düsseldorf, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lauria G, Bakkers M, Schmitz C, Lombardi R, Penza P, Devigili G, Smith AG, Hsieh ST, Mellgren SI, Umapathi T, Ziegler D, Faber CG, Merkies IS. Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. J Peripher Nerv Syst. 2010 Sep;15(3):202-7. doi: 10.1111/j.1529-8027.2010.00271.x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-1556
Identifier Type: OTHER
Identifier Source: secondary_id
SFN children
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.